TTOO News and Press, T2 Biosystems Inc. From 10/20/22

LEXINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has initiated studies to expand the number of pathogens detected on the FDA-cleare...

T2 Biosystems ( NASDAQ: TTOO ) is trading 14% higher after the company said studies showed positive data for the use of T2 Biosystems’ products, T2 Magnetic Resonance Technology. The company said the T2 Biosystems’ products can quickly and accurately dete...

LEXINGTON, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the publication of three new, peer-reviewed studies that demonstrate the clinical value of...

T2 Biosystems ( NASDAQ: TTOO ) said on Thursday it had planned to to complete development of, and commercialize, a diagnostic test to detect early Lyme disease. The company expects to begin marketing and sales in the United States as a Laboratory Developed Te...

LEXINGTON, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today plans to complete development of, and commercialize, a diagnostic test for the detection of earl...

T2 Biosystems ( NASDAQ: TTOO ) reported prelim Q3 revenue of ~$3.7M vs. consensus of $7.19M, down 50% year-over-year due to by lower sales of COVID-19 tests and reduced BARDA revenue offset by increased sepsis test sales. It also updated its 2022 outlook to reflect a mod...

LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the third quarte...

LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the Company’s board of directors (the “Board&#...

Biomedical Advanced Research and Development Authority (or BARDA) is providing T2 Biosystems ( NASDAQ: TTOO ) an additional $3.7M in funding for the multiple-year cost-share contract. BARDA is a part of the Office of the Assistant Secretary for Preparedness and Respon...

LEXINGTON, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Offi...